Viridian Therapeutics, Inc. VRDN
Nov 5, 2026, 11:58 AM EST
- YTD
- -5.70%
- 1 year
- +20.17%
- Market cap
- 3.33B
- Revenue (ttm)
- 71.13M
- EPS (ttm)
- -3.85
- Shares out
- 113.29M
- Forward P/E
- -10.72
- YTD return
- -5.70%
- 1-year return
- +20.17%
- Volume
- 1.76M
- Avg volume
- 2.01M
- Open
- 29.58
- Previous close
- 29.06
- Day's range
- 28.48 – 29.61
- 52-week range
- 13.18 – 34.29
- Beta
- 1.07
- Analysts
- Strong Buy
- Price target
- 36.20 (+23.4%)
- Earnings date
- Feb 25, 2027
5D +4.66 (+19.10%)
Key statistics
- Enterprise value
- 2.21B
- PEG ratio
- 0.00
- Price / sales
- 46.28
- Price / book
- 5.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 278.70%
- Free cash flow
- -275.50M
- Total cash
- 981.53M
- Total debt
- 244.73M
- Return on equity
- -65.74%
- Short % of float
- 16.47%
- 50-day average
- 21.70
- 200-day average
- 21.68
Analyst view
Consensus: strong buy
- Target (low)
- 22.00
- Target (mean)
- 36.20
- Target (high)
- 50.00
- Strong buy3
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.94748.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.94 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.02 | -0.81 | +0.21 | +20.59% |
| Aug 6, 2026 | Jun 30, 2026 | -1.03 | -1.05 | -0.02 | -1.94% |
| May 5, 2026 | Mar 31, 2026 | -1.06 | -0.90 | +0.16 | +15.09% |
| Feb 26, 2026 | Dec 31, 2025 | -0.90 | -1.08 | -0.18 | -20.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.82 | -0.34 | +0.48 | +58.54% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Needham | main | Buy | Buy |
| Sep 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jun 30, 2026 | RBC Capital | main | Outperform | Outperform |
| Jun 30, 2026 | Truist Securities | main | Buy | Buy |
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- viridiantherapeutics.com
News
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42 
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34 - Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Raises Price Target to $33
- Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $42
McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday 
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead 
HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $40 
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call 
Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $38 
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on VRDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 13,361 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 0 |
| HARMON SETH | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 7,790 |
| MAHONEY STEPHEN F | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 33,349 |
| TOUSIGNANT JENNIFER | Officer | Sale | Aug 18, 2026 | 0 |
| TRIPURANENI RADHIKA | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 40,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.66% | 16,604,740 | 482.45M | Jun 29, 2026 |
| Blackrock Inc. | 7.55% | 8,551,488 | 248.46M | Jun 29, 2026 |
| Bellevue Group AG | 5.94% | 6,731,909 | 195.60M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.93% | 6,723,788 | 195.36M | Jun 29, 2026 |
| Kynam Capital Management, LP | 5.70% | 6,453,877 | 187.52M | Jun 29, 2026 |
| State Street Corporation | 5.41% | 6,124,976 | 177.96M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.95% | 3,336,970 | 96.96M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 2,590,081 | 75.25M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 2,495,461 | 72.51M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.57% | 1,782,464 | 51.79M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.32% | 1,500,000 | 43.58M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.28% | 1,447,742 | 42.06M | Jun 29, 2026 |